Background The cyclin-dependent kinase inhibitor Xavopiridol increases irinotecan-and Xuorouracil-induced apoptosis. We conducted a phase I trial of FOLFIRI + Xavopiridol in patients with advanced solid tumors. Design FOLFIRI + Xavopiridol were administered every 2 weeks. Based on sequence-dependent inhibition, Xavopiridol was given 3 h after irinotecan but before 5-FU. Two maximum tolerated doses were determined, one with Xavopiridol administered over 1 h, and one with Xavopiridol split as a 30-min bolus followed by a 4-h infusion.
Introduction
Progression through the phases of the cell cycle is driven by the coordinated activation of the cyclin-dependent kinases (CDK). Deregulated CDK activity is frequently present in malignant cells and inhibition of CDKs can lead to cell cycle arrest and subsequent apoptosis [1, 2] . Modulation of the cell cycle also contributes to chemotherapy resistance. This rationale led to the development of CDK inhibitors as novel antitumor agents.
Flavopiridol is one of the Wrst CDK inhibitors to enter clinical trials. It is prepared by total synthesis and is identical to a compound derived from Dysoxylum binectariferum, a plant indigenous to India [3] . Flavopiridol inhibits CDKs including CDK1, CDK2, CDK4, and CDK6, and it inhibits tumor cell growth in vitro through blockade of cell cycle progression at the G 1 -S or G 2 -M interfaces [4, 5] .
Although phase I studies showed safety and some encouraging clinical activity, single agent phase II trials in solid tumors have been disappointing [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . In contrast, robust signiWcant single agent activity with tumor lysis syndrome has been observed in chronic lymphocytic leukemia, especially when the schedule of administration is altered to improve the drug's pharmacokinetics [6] .
There is evidence that Xavopiridol may improve the eYcacy of cytotoxic chemotherapy, including irinotecan [16] [17] [18] [19] [20] . In our xenograft studies, tumor regressions and pathologic cures were shown without signiWcant toxicity in HCT-116 tumor-bearing mice treated with irinotecan followed by Xavopiridol. We have previously reported a phase I trial of the sequential combination of irinotecan and Xavopiridol [12] . There was encouraging clinical activity in patients with refractory colorectal cancer. Of 27 evaluable patients with colorectal cancer, there was one partial response and 14 patients with stable disease. Median disease control duration for those patients was 6.8 months. Remarkably, the majority of the evaluable patients had received prior irinotecan, thus suggesting that Xavopiridol can modulate the eVect of chemotherapy and overcome tumor resistance.
In addition to encouraging clinical activity, we have also reported a proposed mechanism of action: By inhibiting CDK9, Xavopiridol suppresses expression of Rad51, a DNA repair protein involved in homologous recombination, and thus sensitizes cells to p53-dependent induction of apoptosis by topo I poisons [21] .
To build on the encouraging results of the irinotecanXavopiridol study, we chose the FOLFIRI regimen as the backbone for this clinical trial. The FOLFIRI regimen is used widely as a regimen for metastatic colon cancer [22] . We studied the addition of Xavopiridol to the combination of irinotecan, Xuorouracil, and leucovorin in a rational approach to improve on the three-drug combination. Based on pre-clinical data showing sequence-dependent antitumor eVects, Xavopiridol was given 3-7 h after irinotecan but before 5-FU [21] .
At the recommended phase II dose, additional patients were treated to better deWne the toxicity proWle of the combination. In addition, we have previously reported that the expression of wild-type p53 status at baseline appeared to be predicative of clinical beneWt to Xavopiridol combined with irinotecan [12] . Therefore, pre-therapy tumor samples were examined for p53 status.
The primary objective of this trial was to determine the maximum tolerated dose (MTD) of Xavopiridol, as either a 1-h bolus or a 30-min bolus followed by a 4-h infusion, when administered in combination with FOLFIRI in patients with advanced solid tumors. Secondary objectives were to investigate the clinical pharmacokinetics of Xavopiridol in combination with FOLFIRI, and to obtain preliminary data on the therapeutic activity of this regimen.
Patients and methods

Eligibility
Male and female patients ¸18 years of age with a diagnosis of pathologically conWrmed measurable or evaluable advanced solid tumor, with disease that was refractory to standard therapy or for which there was no standard therapy, were eligible. Patients had to have a Karnofsky performance status ¸60%, total WBC count ¸3,500/mm 3 , absolute neutrophil count ¸1,500/mm 3 , platelet counţ 100,000/mm 3 , and adequate hepatic, renal and cardiac function. Patients could have received prior chemotherapy (including irinotecan and 5-FU), immunotherapy, hormonal therapy, or radiotherapy for their disease, but 4 weeks from last dose had to elapse before study entry (6 weeks for nitrosoureas and mitomycin C). Patients with central nervous system metastasis or a primary central nervous system neoplasm were not eligible.
The protocol was approved by the Institutional Review Board of Memorial Sloan-Kettering Cancer Center and all patients provided written informed consent.
Treatment plan
This was an open-label, non-randomized dose escalation study to determine the maximum tolerated dose (MTD) of FOLFIRI in combination with Xavopiridol. Groups of three to six patients were treated sequentially according to the dose escalation in Table 1 . Treatment was every 2 weeks, provided the absolute neutrophil count (ANC) was1 ,500/mm 3 and platelet count ¸100,000/mm
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. One cycle consisted of 3 treatments in 6 weeks. Patients received irinotecan as a 90-min (cohorts 1-6) or 30-min infusion (cohorts 7-12) based on changing institutional guidelines for irinotecan administration. Seven hours (cohorts 1-6) or 3 h (cohorts 7-12) after the completion of the irinotecan, patients received Xavopiridol as either a 1-h bolus (cohorts 1-10) or 30-min bolus followed by a 4-h infusion (cohorts 11 and 12). Immediately following Xavopiridol, patients received leucovorin over 30 min followed by Xuorouracil as a bolus infusion, and the Xuorouracil as a 48-h continuous infusion. Because of concerns for tumor lysis syndrome with the split-dose schedule, the day following therapy, tumor lysis bloods were obtained including LDH, calcium, magnesium, and phosphorous.
The starting dose was based on an earlier study that determined the MTD of Xavopiridol to be 50 mg/m 2 when combined with irinotecan at 125 mg/m 2 given weekly for 4 of every 6 weeks [12] . Flavopiridol was reduced to 40 mg/ m 2 and FOLFIRI was attenuated with a reduction of Xuorouracil to 1,800 mg/m 2 over 48 h ( Table 1 ). The starting dose of irinotecan was 180 mg/m 2 . Due to excessive toxicity (neutropenic fever), irinotecan was reduced in cohort 3. In addition, entry criteria were changed such that no more than two prior therapies were allowed and patients who had documented grade 4 neutropenia with prior irinotecan in the absence of Xavopiridol were excluded from the trial. Fluorouracil was escalated next to the full dose of 2,400 mg/m 2 in cohort 4. Escalation of irinotecan alternated with escalation of Xavopiridol until the full irinotecan dose of 180 mg/m 2 was reached (cohort 7). With the Wxed fulldose FOLFIRI, Xavopiridol escalation continued (cohort 8, 9 and 10) until the MTD was determined.
At the MTD with bolus Xavopiridol, the study was expanded to evaluate the combination of FOLFIRI with divided-dose Xavopiridol, a pharmacokinetically derived schedule shown to be active in patients with refractory chronic lymphocytic leukemia [6] . Flavopiridol was reduced by one dose level from the MTD and half the dose was administered as a bolus over 30 min immediately followed by the remaining half as a continuous infusion given over 4 h (cohort 12). Flavopiridol was further escalated (cohort 13). The Wnal MTD cohort was expanded with additional patients to assess preliminary eYcacy.
All treatments were administered in the outpatient setting, and once assigned to a dose level, dose escalation within a patient was not permitted.
Toxicity was graded in accordance with the Common Toxicity Criteria version 3.0 [23] . Dose-limiting toxicity (DLT) was deWned as the occurrence during the Wrst cycle of Grade 4 hematologic toxicity, Grade 3 or 4 non-hematologic toxicity including diarrhea despite antidiarrheal prophylaxis, nausea despite maximum anti-emetic therapy, or any delay in treatment resulting in fewer than 3 treatments in the Wrst 6-week cycle. The maximum tolerated dose (MTD) was deWned as the dose one level below the dose at which two or more of the patients in the initial dose level experience DLT during the Wrst treatment course. Patients who experienced a DLT, or toxicity attributed to study medication, could continue to receive study treatment after recovery with appropriate dose modiWcations as deWned per protocol.
To be evaluable for response and to be assessable for determination of MTD, patients had to have received at least one full cycle of therapy. Otherwise, treatment responses were evaluated after every two cycles with computed tomography scans or other diagnostic tests, as appropriate. Response evaluation criteria in solid tumors were used for response assessment and done by an independent protocol radiologist. Complete or partial responses were conWrmed by repeat studies 4 weeks after the criteria for response were Wrst met. 
Statistical design
The main objective of this study was to determine the MTD of Xavopiridol when administered in combination with a FOLFIRI. Standard 3 + 3 design was used for dose escalation. The incidence of hematologic and non-hematologic toxicities was summarized separately by Xavopiridol cohort. Secondary analyses included a pharmacokinetic analysis of Xavopiridol by non-compartmental methods.
Pharmacokinetics
For each patient, blood samples for pharmacokinetics were collected into heparin-coated tubes. Flavopiridol levels were measured on the Wrst day of treatment at the following times-For patients treated with bolus XavopiridolImmediately before and at the end of the 1 h bolus infusion. For patients treated with divided-dose XavopiridolImmediately before treatment, after the 30-min bolus, and at the end of the 4 h infusion.
To assess the level of Xavopiridol, the compound was Wrst isolated from plasma with a liquid-liquid phase extraction and followed by a high-performance liquid chromatography (HPLC)/tandem mass spectrometry (Sciex API 4000, Applied Biosystems, Foster City, CA, USA) analysis using an electrospray ionization method in the positive ion mode. Prior to liquid-liquid phase extraction, frozen plasma samples were thawed at ambient temperature. The liquid-liquid phase extraction was done in a solvent mixture of acetonitrile and methanol (4/1, v/v). The supernatant was injected onto a C18 column. HPLC was then used to separate the compound from any potential interference and measured by the MS/MS detection method, calibration curves were determined for the compound (402 [M + H] +) to permit conversion of peak areas to compound amounts against external reference standards. The tandem MS/MS detector also permits veriWcation of peak identity as well as a quantitative assessment of the compounds in the samples. The limit of quantitation for Xavopiridol was less than 0.01 nM.
Biological assays
Pre-treatment tumor samples of patients enrolled in the expanded cohort at the MTD were evaluated for p53 status. The biopsy specimens were Wxed in formalin and embedded in paraYn. Five-micrometer-thin sections were cut for H&E and immunohistochemistry staining. Monoclonal antibody for p53 (PAb1801, Oncogene Calbiochem, Cambridge, MA, USA) was used at a concentration of 0.2 g/ml as previously described [12] . Both positive and negative controls were run at the time of each experiment. Nuclear staining was considered speciWc reactivity for p53, and the percent of positive tumor cells was estimated examining diVerent Welds throughout the entire tissue section. The staining was reviewed by a pathologist. Mutant (or positive) p53 staining was considered if greater than 20% of the nuclei stained positive.
Results
Patient characteristics
From 10/8/02 to 6/19/08, 74 patients with advanced solid tumors were registered and treated. Eleven of these were not evaluable for determining DLT because they did not complete one cycle (6 weeks) of treatment. The reasons were clinical deterioration (3 patients), withdrawal of consent (3 patients), adverse eVects of 5-FU/leucovorin (3 patients), and protocol non-adherence (2 patients). A further seven patients were not evaluable for determining response because they did not continue treatment until the Wrst restaging scan. The reasons were withdrawal of consent (6 patients) and clinical deterioration (1 patient). Table 2 lists the patient characteristics of the 74 patients who were treated. 63 were evaluable for toxicity and 56 for response.
The median age was 60 years (range, 19-83 years) and the median Karnofsky performance status was 90% (range, 70-90%). There were 43 men and 31 women. The cancers treated and patient numbers were colorectal (31), pancreas (7), melanoma (6), bladder (4), gastric (4), breast (3), cholangiocarcinoma (2), GE junction (2), lung (2), small bowel (2), and others (11). All patients had received prior chemotherapy; 39 (53%) patients had received prior irinotecan. Table 3 lists the most common grade 2-4 hematologic and non-hematologic toxicities for the Wrst cycle of therapy. In the second cohort, two patients had DLT with grade 4 neutropenic fever. Both of these patients were heavily pretreated and had had neutropenia from prior irinotecan, making it impossible to distinguish neutropenia due to irinotecan alone from that of combination therapy. Therefore, this resulted in a protocol initiated amendment to limit the number of prior regimens to two and to exclude patients with documented grade 4 neutropenia from prior irinotecan therapy. This also led to the dose reduction of irinotecan in the next cohort. The next two cohorts completed cycle 1 without a DLT. In cohort 5, one of three patients had a DLT with grade 3 fatigue. The cohort was expanded to include six evaluable patients with no further DLT observed. Dose escalation continued. In cohort 8, one patient had DLT with grade 4 neuropathy. The cohort was expanded with no further DLT in six evaluable patients. In cohort 9, one patient had protocol-deWned DLT since mild thrombocytopenia (<100,000/mm 3 ) resulted in less than 3 treatments in 6 weeks. No further DLT was seen in six evaluable patients. In cohort 10, one patient had grade 4 diarrhea, one patient had grade 3 diarrhea (both despite maximal antidiarrheal therapy) and one patient again had a protocoldeWned DLT since treatment had to be delayed for thrombocytopenia. Thus, cohort 9 (Xavopiridol 80 mg/m 2 ) was declared the MTD for the bolus schedule.
Cycle 1 toxicities
In the split-dose Xavopiridol cohort 11, one of the Wrst three patients had a DLT with grade 4 neutropenia. There was no further DLT in the next three patients treated at that dose. In cohort 12, three of six patients had DLT with grade 3 diarrhea, grade 4 leukopenia, and treatment delay due to neutropenia. Cohort 11 was thus declared the MTD for the split-dose Xavopiridol schedule. This cohort was expanded with ten additional patients. Three of those had DLT with grade 3 diarrhea (two patients) and grade 3 fatigue. The DLT rate for the whole MTD cohort was 25% (4/16). This was considered acceptable using pre-speciWed guidelines since the upper limit of the 95% posterior interval was 40% [24] . Tumor lysis was not observed in any patient. Table 4 lists the most common grade 2-4 cumulative hematologic and non-hematologic toxicities. The cumulative pattern of toxicity was similar to that in cycle 1 of treatment and principally included gastrointestinal and myelosuppressive eVects. The most common grade 3/4 toxicities were neutropenia (29%), lymphopenia (24%), leukopenia (24%), diarrhea (17%), thrombosis or embolism (8%), fatigue (8%), and nausea/vomiting (7%). Table 4 lists the most common grade 2-4 cumulative toxicities for patients overall and grouped by Xavopiridol schedule (bolus vs. split-dose). Grade 3/4 diarrhea occurred in 24% of patients on the split-dose schedule vs. 14% of those on the bolus schedule. Similarly, grade 3/4 neutropenia and lymphopenia each occurred in 43% of patients on the split-dose schedule. In the bolus schedule, the rate was 14% (lymphopenia) and 21% (neutropenia). In contrast, neutropenic fever occurred in 7% of the patients on the bolus schedule, but none of the patients on split-dose schedule.
Cumulative toxicities
One patient with pancreas cancer died of pulmonary embolism and pneumonia 38 days after receiving the Wrst and only treatment with FOLFIRI and Xavopiridol. This event was considered to be due to disease progression rather than to toxicity from treatment.
Pharmacokinetics
Blood samples for pharmacokinetic analyses were obtained for 71 patients. Table 5 summarizes maximum observed plasma concentration (C max ) across all subjects in a cohort. C max for Xavopiridol ranged from 1.65 (SD 0.34) M (at Xavopiridol dose 40 mg/m 2 ) up to a maximum of 4.89 (SD 1.22) M (at Xavopiridol dose 90 mg/m 2 ). In the setting of varying irinotecan dose with constant Xavopiridol dose (cohorts 2-5; cohorts 6 and 7), there was no signiWcant change in Xavopiridol C max , suggesting no interaction between irinotecan dose and Xavopiridol levels. There was signiWcant interpatient variability. At MTDs, there was higher C max in patients who experienced DLT (3.48 M) vs those who did not (2.21 M), but the trend did not meet statistical signiWcance.
Antitumor activity
Fifty-six patients were evaluable for response assessment (Table 6 ). There were two partial responses (small bowel cancer; bladder cancer) and one complete response (mucosal melanoma). Twenty-two patients had stable disease (median 5.9 m; range 1.5-25.7 m). The clinical beneWt rate (CR + PR + SD for >3 m) was 39% (22/56).
Of 25 patients with colorectal cancer, 11 had as best response SD for >3 m (median 6 m, range 4.2-15.4 m). Although prior treatment with irinotecan was neither required nor prohibited for enrollment on this trial, it happened that these 11 had all received and failed at least one prior irinotecan-containing regimen. The median time since prior irinotecan treatment was 2.1 m (range 0.7-11.0 m). In addition to prolonged stable disease, 6 of those 11 patients had marked decreases (36-78%) in CEA. Table 4 Cumulative toxicities The patient who achieved a complete response had a history of anal mucosal melanoma that had been resected. The patient subsequently developed metastases to thoracic, abdominal, and pelvic lymph nodes. Metastatic melanoma was conWrmed by needle biopsy and therapy with FOLFIRI and Xavopiridol began. After 10 months of treatment on protocol, the patient achieved a complete response with resolution of all hypermetabolic lesions. The patient was then observed oV treatment. A follow-up scan 6 months later detected a hypermetabolic inguinal lymph node. This was resected and showed nodal melanosis and hemorrhage with no evidence of viable melanoma. The patient remains alive and without evidence of recurrence now 17 months after starting treatment with FOLFIRI and Xavopiridol.
Correlative studies All 9 patients enrolled in the expanded cohort at the MTD (cohort 12) had tumor assessed for p53 status. These included 4 patients with melanoma, 2 with colorectal cancer, and 1 each with esophagus, lung, and basal cell carcinoma. All samples showed tumor on H & E staining and were adequate for subsequent immunohistochemical analysis for p53. Based on pre-clinical studies indicating that Xavopiridol enhanced the eVect of the DNA-damaging agent irinotecan in a p53-dependent manner, we hypothesized that patients with pre-treatment wild-type p53 would respond better than patients with mutant p53. Supporting this hypothesis, 2 of 3 patients with wild-type p53 had a best response of SD (6.3 m and 11.0 m), whereas 4 of 5 patients with mutant p53 had a best response of PD. The Wfth patient with mutant p53 had SD of only brief duration (2.3 m).
Discussion
Based on the pre-clinical evidence that Xavopiridol enhances the eVect of irinotecan, we conducted a phase I trial of Xavopiridol plus FOLFIRI in patients with advanced solid tumors. [12, 16] . DLTs including diarrhea, fatigue, and neutropenia were similar to other reports and were generally tolerable and manageable. We conclude that Xavopiridol can be combined with FOLFIRI chemotherapy safely.
The eligibility criteria were modiWed during the course of the trial so that patients with prior severe myelosuppression due to irinotecan were excluded. Thus, this may have selected patients with less genetic predisposition to irinotecan toxicity. Therefore, the MTDs only strictly apply to those patients.
In terms of safety, it is not possible to make a deWnite determination whether the bolus schedule or the split-dose schedule is preferred for future clinical development of this combination therapy. Neutropenia, which was an early issue with the bolus schedule, could be ameliorated with careful patient selection. Though dose-limiting diarrhea was observed at both MTDs, it appeared more common with the split-dose schedule. Neutropenia and lymphopenia also appeared somewhat more common with the split-dose schedule. In addition, though interpatient variability was considerable at all dose levels, both schedules resulted in mean Xavopiridol C max that tended to exceed 2 M. As clinical beneWt was observed with both schedules, it also does not appear that maintaining constant exposure to Xavopiridol for an additional 4 h resulted in a dramatic improvement in response rate. The only exception to this could be the patient with mucosal melanoma who achieved the CR on the split-dose schedule. However, whether this was due to the schedule or simply to the combination therapy itself is unknown. Furthermore, unlike the studies that utilize the split-dose schedule in the treatment of CLL, we observed no evidence of tumor lysis syndrome in any one patient. Therefore, based on simply patient convenience, the bolus schedule would seem to be preferred for future development of Xavopiridol with FOLFIRI.
Correlative studies support the hypothesis that Xavopiridol eYcacy depends on an intact p53 axis. Of patients treated at the expanded MTD cohort, most with wild-type p53 had clinical beneWt from treatment in the form of prolonged stable disease, whereas most with mutant p53 had no beneWt. This hypothesis is about to be tested in a clinical trial where patients with metastatic gastric cancer whose tumors are wild-type for p53 will be randomized to irinotecan and Xavopiridol or irinotecan alone.
Encouraging periods of prolonged stable disease were noted in several patients with colorectal cancer who had previously had progressive disease on irinotecan-based therapy. Patients with colorectal cancer treated on this trial had progression-free survival (PFS) rates of 44% (11/25) at 3 months and 24% (6/25) at 6 months. This suggests that Xavopiridol may modulate the eVectiveness of chemotherapy and overcome drug resistance. However, irinotecanresistance was not strictly deWned as it was, for example, in the trial showing that cetuximab can overcome irinotecanresistance [25] . Thus, the hypothesis that Xavopiridol can modulate irinotecan-resistance would need to be formally tested in a prospective trial with a strict deWnition of irinotecan-resistance in the eligibility criteria.
Partial responses in bladder cancer and small bowel cancer were also seen, although whether the eVect was predominantly due to Xavopiridol or to FOLFIRI cannot be determined. More striking, however, is a complete response in mucosal melanoma, a notoriously chemotherapy-resistant disease. Although irinotecan, both alone and in combination with the Xuoropyrimidine capecitabine, has previously been reported to have some activity in melanoma [26, 27] , there is reason to believe a cell cycle inhibitor such as Xavopiridol may be active in this disease.
Among the genetic pathways involved in the development of melanoma, both CDK4 and CCND1 (cyclin D1) are essential. In an examination for genome-wide alterations among 126 melanomas, cyclin D1 resided in the most common genomic region aVected by focused ampliWcation [28] . CDK4, whose protein is one of the binding partners of Cyclin D1 and which is located on chromosome 12q14, was also subject to recurrent ampliWcations. Interestingly, there was a striking inverse correlation between BRAF mutations and increases in the copy numbers for both CDK4 and Cyclin D1. Thus, CDK4 and Cyclin D1 appear to be independent oncogenes in melanoma and they are ampliWed most commonly in melanomas that are wild type for B-RAF. For cyclin D1, this association was independent of the type of melanoma (acral, mucosal, chronic sun induced, and non-chronic sun induced), though for CDK4 the ampliWcations were more commonly observed in the acral or mucosal melanoma subtypes. Thus, melanomas of the mucosal subtype may be more sensitive to an inhibitor such as Xavopiridol. Although a previous phase II study of single agent Xavopiridol found no objective responses in 16 patients, there were likely not enough patients with mucosal melanoma to detect activity [8] . Therefore, further study of Xavopiridol in combination with chemotherapy for mucosal melanoma is warranted.
